CalciMedica (CALC) Projected to Release Earnings on Tuesday

CalciMedica (NASDAQ:CALC) is projected to issue its results before the market opens on Tuesday, August 11th. Analysts expect CalciMedica to post earnings of ($0.33) per share for the quarter.

CalciMedica Trading Up 7.9%

Shares of CALC stock traded up $0.06 on Tuesday, reaching $0.81. The company’s stock had a trading volume of 84,315 shares, compared to its average volume of 1,103,677. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The stock’s fifty day simple moving average is $0.83 and its 200-day simple moving average is $1.04. The company has a market capitalization of $12.83 million, a price-to-earnings ratio of -0.62 and a beta of 0.91.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CalciMedica has an average rating of “Hold” and an average target price of $10.00.

Insiders Place Their Bets

In other news, Director Fred A. Middleton acquired 248,972 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 28.25% of the company’s stock.

Institutional Trading of CalciMedica

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers grew its position in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the period. Jane Street Group LLC acquired a new stake in shares of CalciMedica in the fourth quarter valued at about $127,000. Envestnet Asset Management Inc. increased its stake in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of CalciMedica during the fourth quarter worth approximately $506,000. Finally, Renaissance Technologies LLC raised its position in shares of CalciMedica by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after buying an additional 18,300 shares during the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.